02244nam a2200457 i 4500001001300000003000600013005001700019007001400036008004100050040003000091042000800121043001200129074001600141086002000157088009000177110007400267245024000341246004900581246007300630264006000703300002700763336000800790337001600798338001900814500002500833500003600858500005500894533010600949776014501055776012801200050002101328610002701349650005301376650005901429650004701488650006001535650007101595650003501666650005201701655003301753on1140549210OCoLC20200313193136.0he bmb024bbca200213s2019    dcu     b    f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---  a1016-B (MF)0 aY 4.OV 2:116-24  aSerial no. 116-24 (United States. Congress. House. Committee on Oversight and Reform)1 aUnited States.bCongress.bHouse.bCommittee on Oversight and Reform,10aHIV prevention drug  :bbillions in corporate profits after millions in taxpayer investments : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, May 16, 2019.3 aHuman Immunodeficiency Virus prevention drug30aBillions in corporate profits after millions in taxpayer investments 1aWashington :bU.S. Government Publishing Office,c2019.  aiii, 63 pages ;c24 cm  btxt  bh2rdamedia  bhe2rdacarrier  a"Serial no. 116-24."  aShipping list no.: 2020-0010-M.  aGPO Cataloging Record Distribution Program (CRDP).  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2019]e1 microfiche : negative.08iPrint version:aUnited States. Congress. House. Committee on Oversight and Reform.tHIV prevention drugw(DLC) 2019394984w(OCoLC)111235679808iOnline version:aUnited States. Congress. House. Committee on Oversight and Reform.tHIV prevention drugw(OCoLC)1112074275 4aKF27b.O96 2019i20aGilead Sciences (Firm) 0aPre-exposure prophylaxisxPriceszUnited States. 0aPre-exposure prophylaxiszUnited StatesxCost control. 0aHIV infectionszUnited StatesxPrevention. 0aPrescription pricingxGovernment policyzUnited States. 0aPharmaceutical industryxPricesxGovernment policyzUnited States. 0aMedical policyzUnited States. 0aFederal aid to medical researchzUnited States. 7aLegislative hearings.2lcgft